Literature DB >> 30084209

Surgical treatment strategy for advanced hepatoblastoma: Resection versus transplantation.

Hajime Uchida1, Seisuke Sakamoto1, Kengo Sasaki1, Masahiro Takeda1, Yoshihiro Hirata1, Akinari Fukuda1, Tomoro Hishiki1, Rie Irie2, Atsuko Nakazawa2, Osamu Miyazaki3, Shunsuke Nosaka3, Mureo Kasahara1.   

Abstract

BACKGROUND: Excellent outcomes of the extreme procedure of liver resection (LR) for advanced hepatoblastoma (HB) have been achieved in recent reports. However, liver transplantation (LT) remains the only surgical treatment for patients with unresectable HB. The aim of this study was to evaluate our retrospective data for cases of advanced HB necessitating surgical intervention and analyze the prognostic factors of recurrence by comparing patients with tumors resected by LR and LT. PATIENTS AND METHODS: We retrospectively reviewed 24 children with PRETEXT II/III/IV tumors that required consideration for LT between August 2011 and September 2016. RESULT: The staging at the time of the diagnosis was PRETEXT II/III/IV in 1/13/10 patients, respectively, while the preoperative staging after neoadjuvant chemotherapy was POSTTEXT II/III/IV in 5/17/2 patients. Among those 24 patients, complete resection of the primary tumor was achieved with LT in 12 patients and LR in 12 patients. A high serum level of alpha-fetoprotein (AFP) at the time of surgery, no significant decrease in the rate of change of AFP, and low tumor shrinkage rate were related to the risk of tumor recurrence, and patients with tumors resected by LR with those risks had a higher recurrence rate than those without them. The overall survival was higher in patients with tumors resected by LT (100%) than in patients with tumors resected by LR.
CONCLUSION: Patients with advanced HB with a poor response to chemotherapy should definitively be prioritized for primary LT, given the possibility of vascular invasion and microscopic residual tumor.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  PRETEXT III; PRETEXT IV; hepatoblastoma

Mesh:

Substances:

Year:  2018        PMID: 30084209     DOI: 10.1002/pbc.27383

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Impact of microscopically margin-positive resection on survival in children with hepatoblastoma after hepatectomy: a retrospective cohort study.

Authors:  Xianghai Ren; Haibo Li; Mei Diao; Hang Xu; Long Li
Journal:  Int J Clin Oncol       Date:  2019-11-07       Impact factor: 3.402

Review 2.  Current Approaches in Hepatoblastoma-New Biological Insights to Inform Therapy.

Authors:  Peng V Wu; Arun Rangaswami
Journal:  Curr Oncol Rep       Date:  2022-04-19       Impact factor: 5.945

3.  Different anaesthesia methods affect the development of hepatoblastoma after platelet activation.

Authors:  Guoxiong Fei; Meili Cao; Chunlin Ge; Yan Xie
Journal:  Int J Exp Pathol       Date:  2021-01-07       Impact factor: 1.925

Review 4.  How Do Synchronous Lung Metastases Influence the Surgical Management of Children with Hepatoblastoma? An Update and Systematic Review of the Literature.

Authors:  Roberta Angelico; Chiara Grimaldi; Carlo Gazia; Maria Cristina Saffioti; Tommaso Maria Manzia; Aurora Castellano; Marco Spada
Journal:  Cancers (Basel)       Date:  2019-10-31       Impact factor: 6.639

5.  Feasibility of Real-Time Central Surgical Review for Patients with Advanced-Stage Hepatoblastoma in the JPLT3 Trial.

Authors:  Tomoro Hishiki; Shohei Honda; Yuichi Takama; Yukihiro Inomata; Hideaki Okajima; Ken Hoshino; Tatsuya Suzuki; Ryota Souzaki; Motoshi Wada; Mureo Kasahara; Koichi Mizuta; Takaharu Oue; Akiko Yokoi; Takuro Kazama; Shugo Komatsu; Isamu Saeki; Osamu Miyazaki; Tetsuya Takimoto; Kohmei Ida; Kenichiro Watanabe; Eiso Hiyama
Journal:  Children (Basel)       Date:  2022-02-10

6.  The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.

Authors:  Li Liu; Jiangtu He; Guifeng Sun; Nan Huang; Zhixuan Bian; Chang Xu; Yue Zhang; Zhongqi Cui; Wenqiang Xu; Fenyong Sun; Chengle Zhuang; Qiuhong Man; Song Gu
Journal:  Clin Transl Med       Date:  2022-05

7.  Oncogenic Role of ADAM32 in Hepatoblastoma: A Potential Molecular Target for Therapy.

Authors:  Takahiro Fukazawa; Keiji Tanimoto; Emi Yamaoka; Masato Kojima; Masami Kanawa; Nobuyuki Hirohashi; Eiso Hiyama
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.